2023-10-22-深交所-华兰股份_2023年三季度报告_10页_379kb

报告摘要

Financial Performance Summary

The 2023 third-quarter report for Jiangsu Hualan Pharmaceutical New Material Co., Ltd. (Stock Code: 301093) shows strong growth in revenue and net profit compared to the same period in 2022. For the third quarter alone,营业收入 increased by 8.51%, and归属于上市公司股东的净利润 rose by 42.76%. Year-to-date,营业收入 grew 11.42% to 453,754,549.65 yuan, with net profit up 16.50% to 89,306,207.63 yuan. High investment gains and government subsidies contributed to the profit increase.

Key Financial Highlights

Revenue and Profit: Significant growth driven by increased fixed-income investments and government grants, particularly other gains of 21,796,425.99 yuan for the year.
Cash Flow: Strong operating cash flow of 133,591,828.71 yuan, boosted by higher subsidies and low cash outflows from investments.
Non-Recurring Items: Investment gains and government aid accounted for substantial portions of profit growth.
Balance Changes: Increases in other non-current assets and fixed assets reflect expanded operations and investments.

Tangible Changes Explained

Balance Sheet Adjustments: Changes in items like交易性金融资产同比下降 84.61% due to altered investment strategies, while other changes relate to equity funds, plant construction, and inventory additions.
Profit Drivers: Management costs rose due to expanded staffing and depreciation, offset by higher gains from investments. Credit losses decreased after writebacks from reduced receivables.
Cash Flow Fluctuations: Higher cash from investment returns and reduced debt repayment led to net positive cash flow.

Shareholder Information

Shareholders: Top shareholders include entities like Jiangsu Hualan Machinery Tech Co. (20.83% stake) and individual investors, with a total of 18,361 shareholders.
Ownership Structure: No major changes, but the company implemented share repurchase programs under equity incentives.

Overall Conclusion

The company demonstrates resilience and strategic growth, with financial performance supported by deliberate investments and operational improvements, although fiscal scrutiny and non-recurring items influence results.

展开完整摘要